Skip to main content

GSK vs Pfizer: Strategic Comparison

Direct Answer

Pfizer is the larger company by revenue, reporting $62.6 billion for fiscal year 2025 versus GSK's £32.7 billion (about $43.5 billion), a gap of roughly 44%. Despite that, GSK's net income of about £5.7 billion (around $7.6 billion) came within a few hundred million dollars of Pfizer's $7.77 billion, because GSK's 17.5% net margin outpaces Pfizer's 12.4%. Pfizer is run by Chairman and CEO Albert Bourla, while GSK has been led by CEO Luke Miels since January 1, 2026.

Pfizer reported $62.6 billion in FY2025 revenue, roughly 44% more than GSK's £32.7 billion (about $43.5 billion at September 2026 exchange rates), yet the two companies' net income landed almost identical: $7.77 billion for Pfizer against roughly $7.6 billion for GSK. Pfizer traces back to 1849, when Charles Pfizer and Charles Erhart opened a chemical business in Brooklyn, while GSK's lineage runs through a 1715 London pharmacy and the December 2000 merger of Glaxo Wellcome and SmithKline Beecham. Albert Bourla has been Pfizer's Chairman and CEO since January 2019, while GSK handed the top job to Luke Miels on January 1, 2026, succeeding Dame Emma Walmsley. Pfizer employed about 75,000 people and GSK about 66,800 as of their respective FY2025 filings, and both spent 2025 and 2026 on large acquisitions aimed at refilling their drug pipelines: Pfizer closed its roughly $10 billion Metsera obesity deal in November 2025, while GSK completed its $10.6 billion purchase of Nuvalent in July 2026.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldGSK plcPfizer Inc.
Latest annual revenue~$43.1B (FY2025)$62.6B (FY2025)
Founded17151849
Employees66,80075,000
Market Cap$100.0B$160.3B
HeadquartersUnited KingdomUnited States
Revenue / Employee$646k / employee$834k / employee
Valuation Multiple2.3x P/S2.6x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

GSK plc Strategic Vector

FY2025 Revenue Baseline

GSK plc's long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward oncology and liver disease, where nuvalent's lung-cancer drugs, efimosfermin for steatotic liver disease and bepirovirsen for hepatitis B could add new revenue streams, supporting the target of more than $52. Concurrently, the organization focuses on navigating market pressures around us pricing and vaccine policy, addressing environments where uS drug-pricing reforms, tariffs and changes to vaccine recommendations can quickly reduce demand, as shown by the Arexvy slowdown in 2024-2025. By maintaining disciplined capital allocation and operational rigor, GSK plc aims to protect its unit economics and preserve its economic moat across changing market cycles.

Productivity: $646k / employee

Pfizer Inc. Strategic Vector

FY2025 Revenue Baseline

Following the historic pandemic revenue windfall, Pfizer's corporate strategy centers on redeploying capital into high-growth oncology franchises and structural cost alignment. Under Chief Executive Officer Albert Bourla, Pfizer executed the landmark forty-three-billion-dollar acquisition of Seagen Inc., instantly establishing Pfizer as a global powerhouse in targeted cancer therapies. Seagen added four commercialized antibody-drug conjugates (including Padcev, Adcetris, and Tukysa) and doubled Pfizer's oncology pipeline with specialized tumor-homing molecules. Concurrently, Pfizer launched a multi-billion-dollar enterprise cost realignment program to adjust operating expenses to post-pandemic baseline demand, while launching novel vaccines including Abrysvo for respiratory syncytial virus (RSV) protection in infants and older adults.

Productivity: $834k / employee
Comparative Divergence: Pfizer and GSK compete most directly in vaccines: GSK's Arexvy and Pfizer's Abrysvo have gone head-to-head in the RSV vaccine market since both launched in 2023, and GSK held roughly half of global RSV vaccine sales in 2024 even as narrower 2024-2025 US vaccination recommendations cut both companies' RSV revenue sharply. The rivalry extends to meningitis and pneumococcal vaccines, where GSK's Bexsero, Menveo and the 2025-approved Penmenvy compete against Pfizer's Prevnar franchise. Both companies have also raced to rebuild oncology pipelines through acquisitions announced within months of each other, Pfizer's Metsera and Innovent deals against GSK's Nuvalent purchase, as each tries to replace revenue before a major patent cliff later this decade.

GSK vs Pfizer Market Share

GSK plc market share
GSK plc is one of the premier market leaders in Pharmaceuticals & Biotechnology, commanding substantial market share and strong brand equity across its core geographic operating regions.
Pfizer Inc. market share
Pfizer ranks among the top pharmaceutical companies worldwide by revenue. Its strongest positions are in pneumococcal vaccines (Prevnar), anticoagulation (Eliquis, with BMS), ATTR cardiomyopathy (Vyndaqel family) and ADC-based bladder cancer treatment (Padcev).

Quick Stats Comparison

MetricGSK plcPfizer Inc.
Revenue~$43.1B (FY2025)$62.6B (FY2025)
Founded17151849
HeadquartersLondon, United KingdomNew York, New York
Market Cap$100.0B$160.3B
Employees66,80075,000
Revenue / Employee$646k / employee$834k / employee
Valuation Multiple2.3x P/S2.6x P/S

GSK Revenue vs Pfizer Revenue — Year by Year

YearGSK plcPfizer Inc.Higher reported revenue
2025~$43.1B$62.6BPfizer Inc. (approx. USD)
2024~$41.4B$63.6BPfizer Inc. (approx. USD)
2023~$40B$59.6BPfizer Inc. (approx. USD)
2022~$38.7B$101.2BPfizer Inc. (approx. USD)
2021~$32.6B$81.3BPfizer Inc. (approx. USD)

Business Model Breakdown

Overview: GSK plc vs Pfizer Inc.

This in-depth comparison examines GSK plc and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching GSK plc on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between GSK plc and Pfizer Inc. is widest.

On the headline numbers, annual revenue is ~$43.1B (FY2025) for GSK plc and $62.6B (FY2025) for Pfizer Inc., while their respective market capitalizations stand at $100.0B and $160.3B. GSK plc is headquartered in United Kingdom and Pfizer Inc. in United States, and those different home markets shape how each company competes.

GSK plc: GSK plc is listed in London (LSE: GSK) and New York (NYSE: GSK) and is a FTSE 100 constituent. It operates in about 70 countries with 33 manufacturing sites and about 66,800 employees. The company focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Well-known products include Shingrix, Arexvy, Trelegy Ellipta, Ventolin, Nucala, Dovato and Cabenuva. The company is headquartered in London, United Kingdom.

Pfizer Inc.: Pfizer Inc. (NYSE: PFE) is one of the largest pharmaceutical companies in the world by revenue, headquartered at The Spiral, 66 Hudson Boulevard East, New York. It employs about 75,000 people and sells medicines in more than 180 countries. Its history includes Terramycin, Lipitor (via Warner-Lambert), Viagra, Prevnar (via Wyeth) and the Comirnaty COVID-19 vaccine developed with BioNTech. The company is headquartered in New York City, New York. Pfizer was founded in 1849 in Brooklyn, New York City, by German immigrant cousins Charles Pfizer and Charles F. Erhart as a fine-chemicals business, expanding over 175 years into a global biopharmaceutical giant discovering penicillin, Lipitor, Viagra, and the landmark COVID-19 vaccine Comirnaty.

Business Models: How GSK plc and Pfizer Inc. Make Money

GSK plc and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between GSK plc and Pfizer Inc..

GSK plc business model: GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Its sales are reported in three groups. Specialty Medicines (~$17.8 billion (£13.5 billion) in 2025, about 41% of sales) covers HIV through ViiV Healthcare, respiratory and immunology biologics such as Nucala and Exdensur, and oncology drugs such as Jemperli, Ojjaara and Blenrep. Vaccines (~$12.1 billion (£9.2 billion), about 28%) are led by Shingrix for shingles, the Bexsero and Menveo meningitis vaccines and the Arexvy RSV vaccine. General Medicines (~$13.2 billion (£10.0 billion), about 31%) includes established inhalers such as Trelegy and Ventolin and antibiotics like Augmentin. GSK also earns royalty income on licensed products.

Pfizer Inc. business model: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology. Historically recognized for blockbuster small molecules (Lipitor, Viagra, Eliquis) and pediatric vaccines (Prevnar family), Pfizer achieved unprecedented revenue scale by co-developing Comirnaty—the world's first authorized mRNA COVID-19 vaccine—with BioNTech, alongside the oral antiviral Paxlovid. The company monetizes intellectual property through global pharmaceutical distribution networks, selling to national governments, hospital purchasing organizations, and retail pharmacy chains across more than one hundred twenty countries.

Competitive Advantage: GSK plc vs Pfizer Inc.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of GSK plc stack up against those of Pfizer Inc..

GSK plc competitive advantage: GSK's advantages are scale in vaccine manufacturing, a long-acting HIV portfolio through ViiV Healthcare, and the AS01 adjuvant system used in Shingrix and Arexvy. Vaccines are hard to copy because they depend on biological manufacturing, cold-chain distribution and long-term government contracts. ViiV's long-acting injectables, Cabenuva for treatment and Apretude for prevention, aim to move patients onto newer regimens ahead of the dolutegravir patent expiry.

Pfizer Inc. competitive advantage: Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities. Few pharmaceutical corporations in the world possess the logistical capacity to conduct concurrent Phase 3 clinical trials involving tens of thousands of patients across dozens of countries while managing ultra-low-temperature cold-chain distribution. Pfizer's Prevnar pneumococcal conjugate vaccine family has maintained multi-decade commercial dominance due to the extreme complexity of polysaccharide-protein conjugation manufacturing. Pfizer's alliance with Bristol-Myers Squibb on the anticoagulant Eliquis provides reliable, high-margin cash flow, while its commercial relationships with national healthcare authorities enable rapid global drug rollouts.

Growth Strategy: Where GSK plc and Pfizer Inc. Are Headed

Future prospects matter as much as current results. The growth strategies below explain how GSK plc and Pfizer Inc. each plan to expand from here.

GSK plc growth strategy: Under Luke Miels, GSK is combining targeted acquisitions with faster R&D. Deals since 2025 include IDRx (GIST, January 2025), efimosfermin from Boston Pharmaceuticals ($1.2 billion upfront, July 2025) and Nuvalent ($10.6 billion, completed July 2026). In July 2026 GSK identified 7 assets across 18 indications in oncology, respiratory, hepatology and vaccines to speed up, raised its 2026 phase III start target from 10 to more than 20, and launched a cost programme to fund that investment.

Pfizer Inc. growth strategy: Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.

Financial Picture: GSK plc vs Pfizer Inc.

A closer look at the financial trajectory of GSK plc and Pfizer Inc. rounds out the comparison.

GSK plc: GSK reported 2025 turnover of ~$43.2 billion (£32.7 billion) (+4% at actual rates, +7% at constant currency), operating profit of ~$10.4 billion (£7.9 billion), profit attributable to shareholders of ~$7.52 billion (£5.7 billion), and earnings per share of 141.1p. Cash generated from operations was ~$11.7 billion (£8.9 billion) and free cash flow ~$5.28 billion (£4.0 billion). In Q2 2026, sales rose 5% to ~$11.1 billion (£8.4 billion) and core operating profit rose 7% to ~$3.7 billion (£2.8 billion), beating consensus, while reported operating profit fell to ~$635 million (£481 million) because of the camlipixant impairment. H1 2026 turnover was ~$21.1 billion (£16.0 billion). GSK reaffirmed 2026 guidance of 3% to 5% turnover growth and 7% to 9% core operating profit growth, expects a 70p dividend for 2026, and launched a three-year plan targeting ~$2.51 billion (£1.9 billion) of annual savings by 2029. GSK plc is a colossal British multinational pharmaceutical and biotechnology company, commanding a market valuation typically exceeding $70 billion.

Pfizer Inc.: Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Company-Specific SWOT Notes

GSK plc

Strength

Vaccines generated ~$12.1 billion (£9.2 billion) in 2025, led by Shingrix (~$4.75 billion (£3.6 billion)) and meningitis vaccines (~$2.11 billion (£1.6 billion)), backed by large biological manufacturing capacity and the AS01 adjuvant system.

Strength

Specialty Medicines grew 17% to ~$17.8 billion (£13.5 billion) in 2025 and 14% in Q2 2026, with oncology up 43% in 2025.

Weakness

HIV sales of ~$10.2 billion (£7.7 billion) rely heavily on dolutegravir-based regimens, which lose exclusivity between 2028 and 2030.

Weakness

The 2026 decision to stop camlipixant, acquired with Bellus Health in 2023, led to about $1.72 billion (£1.3 billion) of impairments in Q2 2026.

Opportunity

Nuvalent's lung-cancer drugs, efimosfermin for steatotic liver disease and bepirovirsen for hepatitis B could add new revenue streams, supporting the target of more than $52.8 billion (£40 billion) in sales by 2031.

Threat

US drug-pricing reforms, tariffs and changes to vaccine recommendations can quickly reduce demand, as shown by the Arexvy slowdown in 2024-2025.

Pfizer Inc.

Strength

Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.

Weakness

Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.

Weakness

The impending loss of exclusivity for blockbuster drugs like Eliquis and Ibrance threatens a significant portion of Pfizer's high-margin recurring revenue by 2027.

Opportunity

The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.

Threat

Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScalePfizer Inc.~$43.1B (FY2025) versus $62.6B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierGSK plcGSK plc was founded in 1715; Pfizer Inc. was founded in 1849.
Verdict

Comparison Takeaway: GSK vs Pfizer

Pfizer is the bigger, more diversified business, but its scale is a legacy of a COVID-19 windfall it is still unwinding: revenue fell from a $101.2 billion peak in 2022 to $62.6 billion in 2025, and 2026 guidance of $60.5 billion to $62.5 billion implies another roughly flat year. GSK is smaller and more concentrated, with HIV medicines through ViiV Healthcare alone generating ~$10.2 billion (£7.7 billion) in 2025, about 24% of total sales, which makes its 2028-2030 dolutegravir patent cliff a bigger single risk than any one franchise is for Pfizer. GSK's operating discipline shows in the margin numbers, a 17.5% net margin against Pfizer's 12.4%, even after GSK booked a roughly $1.72 billion (£1.3 billion) impairment on a failed cough-drug programme in Q2 2026. Both companies are answering patent risk the same way, buying oncology assets, Pfizer with Seagen ($43 billion, 2023) and Metsera (about $10 billion, November 2025), GSK with Nuvalent ($10.6 billion, July 2026), but Pfizer carries more acquisition-related debt against a market capitalization of about $160 billion versus GSK's roughly £75 billion (about $100 billion).

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: GSK vs Pfizer

Is Pfizer bigger than GSK?

Yes. Pfizer reported $62.6 billion in FY2025 revenue, about 44% more than GSK's £32.7 billion (roughly $43.5 billion at September 2026 exchange rates). Pfizer also has more employees, about 75,000 versus GSK's 66,800.

Which is more profitable, Pfizer or GSK?

GSK is more profitable by margin. Its FY2025 net margin was about 17.5% (~$7.52 billion (£5.7 billion) net income on ~$43.2 billion (£32.7 billion) revenue) versus Pfizer's 12.4% (about $7.77 billion net income on $62.6 billion revenue), even though Pfizer's total profit is slightly higher in dollar terms.

Who is the CEO of GSK and who runs Pfizer?

Luke Miels became GSK's CEO on January 1, 2026, succeeding Dame Emma Walmsley. Albert Bourla has been Pfizer's Chairman and CEO since January 2019.

Does GSK's Arexvy or Pfizer's Abrysvo lead the RSV vaccine market?

GSK's Arexvy held roughly half of global RSV vaccine sales in 2024, ahead of Pfizer's Abrysvo, though both vaccines lost significant US revenue in 2024-2025 after regulators narrowed vaccination recommendations for older adults.

Which is the bigger stock, Pfizer or GSK?

Pfizer has the larger market capitalization, about $160 billion in late September 2026 versus GSK's roughly £75 billion (about $100 billion), reflecting Pfizer's larger revenue base even though GSK's profit margins are higher.

Which company was founded first, GSK plc or Pfizer Inc.?

GSK plc was founded in 1715; Pfizer Inc. was founded in 1849.

What revenue did GSK plc and Pfizer Inc. report?

GSK plc had ~$43.1B (FY2025), while Pfizer Inc. had $62.6B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do GSK plc and Pfizer Inc. make money?

GSK plc: GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which is better, GSK plc or Pfizer Inc.?

There is no evidence-based single winner. Compare GSK plc and Pfizer Inc. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

Pfizer is the larger company by revenue, reporting $62.6 billion for fiscal year 2025 versus GSK's £32.7 billion (about $43.5 billion), a gap of roughly 44%. Despite that, GSK's net income of about £5.7 billion (around $7.6 billion) came within a few hundred million dollars of Pfizer's $7.77 billion, because GSK's 17.5% net margin outpaces Pfizer's 12.4%. Pfizer is run by Chairman and CEO Albert Bourla, while GSK has been led by CEO Luke Miels since January 1, 2026.

Verdict

Pfizer is the bigger, more diversified business, but its scale is a legacy of a COVID-19 windfall it is still unwinding: revenue fell from a $101.2 billion peak in 2022 to $62.6 billion in 2025, and 2026 guidance of $60.5 billion to $62.5 billion implies another roughly flat year. GSK is smaller and more concentrated, with HIV medicines through ViiV Healthcare alone generating ~$10.2 billion (£7.7 billion) in 2025, about 24% of total sales, which makes its 2028-2030 dolutegravir patent cliff a bigger single risk than any one franchise is for Pfizer. GSK's operating discipline shows in the margin numbers, a 17.5% net margin against Pfizer's 12.4%, even after GSK booked a roughly $1.72 billion (£1.3 billion) impairment on a failed cough-drug programme in Q2 2026. Both companies are answering patent risk the same way, buying oncology assets, Pfizer with Seagen ($43 billion, 2023) and Metsera (about $10 billion, November 2025), GSK with Nuvalent ($10.6 billion, July 2026), but Pfizer carries more acquisition-related debt against a market capitalization of about $160 billion versus GSK's roughly £75 billion (about $100 billion).

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). GSK plc vs Pfizer Inc. Comparison. from https://corpdigest.com/compare/gsk-vs-pfizer

MLA Format

CorpDigest. "GSK plc vs Pfizer Inc. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/gsk-vs-pfizer.

Chicago Format

CorpDigest. "GSK plc vs Pfizer Inc. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/gsk-vs-pfizer.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.